Insilico Medicine and SK Biopharmaceuticals Unite to Fast-Track Life-Saving Drug Discovery

The future of medicine is being written in the language of artificial intelligence, and the timeline for creating life-saving treatments is shrinking at an unprecedented pace. At the 2026 BIO International Convention, a major industry milestone was unveiled as Insilico Medicine, a pioneer in AI-native biotechnology, announced a strategic collaboration with global pharmaceutical leader SK Biopharmaceuticals. This partnership marks a monumental shift in how the industry approaches the discovery and development of complex therapies.

The collaboration bridges two distinct industry strengths to tackle some of healthcare's most critical unmet patient needs. Insilico Medicine brings its cutting-edge, AI-driven "target-to-candidate" engine to the table, which acts as a digital accelerator for identifying disease targets and generating molecular blueprints. Meanwhile, SK Biopharmaceuticals provides deep, specialized mastery in Central Nervous System disorders, combined with their powerhouse global leadership and commercialization expertise. By combining these forces, the duo aims to unlock therapeutic breakthroughs spanning both traditional small molecules and highly advanced new modalities.

Read more via the link